Trials / Temporarily Not Available
Temporarily Not AvailableNCT06408727
Intermediate Expanded Access Protocol CNMAu8.EAP04
An Intermediate Expanded Access Protocol With CNM-Au8 for Amyotrophic Lateral Sclerosis for NIH Grant RFA-NS-23-012
- Status
- Temporarily Not Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Clene Nanomedicine · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
An Intermediate Expanded Access Protocol (EAP) with CNM-Au8 for Amyotrophic Lateral Sclerosis for NIH Grant RFA-NS-23-012
Detailed description
An Intermediate Expanded Access Protocol (EAP) with CNM-Au8 for Amyotrophic Lateral Sclerosis for NIH Grant RFA-NS-23-012. The primary objective of this intermediate EAP is to provide access to the investigational product, CNM-Au8 30mg, for up to 180 people living with ALS.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CNM-Au8 | CNM-Au8 (cellular energetic nanocatalyst). Faceted clean-surfaced catalytically-active Au nanocrystals. |
Timeline
- First posted
- 2024-05-10
- Last updated
- 2026-04-07
Locations
8 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT06408727. Inclusion in this directory is not an endorsement.